Graduation Date

Spring 5-8-2021

Document Type


Degree Name

Master of Science (MS)


Pharmaceutical Sciences

First Advisor

Martin Conda-Sheridan

Second Advisor

Paul C. Trippier

Third Advisor

Elizabeth A. Rucks


Chlamydia trachomatis infection is the most commonly reported sexually transmitted disease in the United States and the world. This pathogen can cause long-term health problems including blindness, pelvic inflammatory disease (PID) and ectopic pregnancy, which can be life-threatening if left untreated. To this day, there is no chlamydia-specific drug on the market. The standard treatment uses broad-spectrum antibiotics, which may affect regular functions of the commensal microbiota and leads to the development of bacterial resistance. Recently, a series of compounds based on Activators of Self-Compartmentalizing Proteases (ACP) was reported to show antichlamydial activity. Based on that scaffold, we prepared 21 compounds by doing modifications on it. Biological evaluation studies show that those analogs can halt the growth of Chlamydia trachomatis. The diversity of compounds and antichlamydial activity results point us a direction for further developing selective anti-chlamydia drug.